GSK plc (LON:GSK) Insider Julie Brown Purchases 8 Shares

GSK plc (LON:GSK) insider Julie Brown purchased 8 shares of GSK stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average price of GBX 1,399 ($18.00) per share, for a total transaction of £111.92 ($144.02).

GSK Price Performance

Shares of LON:GSK opened at GBX 1,369.50 ($17.62) on Wednesday. The firm has a 50 day simple moving average of GBX 1,512.80 and a 200 day simple moving average of GBX 1,583.74. The company has a market cap of £55.88 billion, a price-to-earnings ratio of 1,207.08, a PEG ratio of 1.24 and a beta of 0.31. GSK plc has a one year low of GBX 1,352.86 ($17.41) and a one year high of GBX 1,823.50 ($23.47). The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73.

GSK Announces Dividend

The firm also recently declared a dividend, which will be paid on Thursday, January 9th. Stockholders of record on Thursday, November 14th will be paid a dividend of GBX 15 ($0.19) per share. This represents a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, November 14th. GSK’s payout ratio is currently 5,309.73%.

Analysts Set New Price Targets

Several analysts recently issued reports on GSK shares. Berenberg Bank reiterated a “buy” rating and set a GBX 1,820 ($23.42) price target on shares of GSK in a research report on Tuesday, September 10th. Shore Capital reiterated a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,850 ($23.81) price target on shares of GSK in a research report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of GBX 1,842.50 ($23.71).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.